 Home > Biochemistry News > Biotechnology News > Aims to functionally cure hepatitis B RNAi immune combination therapy to carry out phase 2 clinical trials

Aims to functionally cure hepatitis B RNAi immune combination therapy to carry out phase 2 clinical trials

 Last Update: 2022-01-11
 Source: Internet
 Author: User

Tags

binder safety

pdr drug reference

small safety glasses

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On December 9, 2021, Vir Biotechnology announced that a phase 2 clinical trial of a novel combination of RNAi therapy VIR-2218 has completed the first patient administration for the treatment of patients with chronic hepatitis B virus (HBV) infection

VIR-2218 is a subcutaneously administered siRNA targeting the X gene of HBV jointly developed by Vir and Alnylam Pharmaceuticals.

▲Introduction to VIR-2218 (picture source: reference [2])

This multi-center, open-label Phase 2 clinical trial aims to evaluate the safety, tolerability and efficacy of various therapeutic combinations of VIR-2218 in combination with selgantolimod, nivolumab and TAF in the treatment of adult patients with chronic HBV infection

Reference materials:

[1] Vir Biotechnology Announces Initiation of Phase 2 Clinical Trial Evaluating VIR-2218, Selgantolimod and Nivolumab for the Treatment of Chronic Hepatitis B Virus Infection.

[2] Safety and Antiviral Activity of VIR-2218, An X-Targeting RNAi Therapeutic, In Participants With Chronic Hepatitis B Infection: Week 48 Follow-Up Results.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.